Hinova Pharmaceuticals Inc. A (688302) — Cash Flow-to-Debt Ratio
Hinova Pharmaceuticals Inc. A (688302) has a Cash Flow-to-Debt Ratio of -1.10x as of December 2024, meaning its operating cash flow of CN¥-187.08 Million could theoretically repay -1% of its total liabilities (CN¥169.33 Million) in one year. See 688302 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hinova Pharmaceuticals Inc. A Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Hinova Pharmaceuticals Inc. A across 6 annual periods. Also explore Hinova Pharmaceuticals Inc. A annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hinova Pharmaceuticals Inc. A (2019–2024)
Year-by-year debt coverage analysis for Hinova Pharmaceuticals Inc. A. For market capitalisation and broader financial context, see Hinova Pharmaceuticals Inc. A market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.10x | CN¥-187.08 Million | CN¥169.33 Million | ▲ +46.2% |
| 2023 | -2.05x | CN¥-255.51 Million | CN¥124.47 Million | ▲ +2.4% |
| 2022 | -2.10x | CN¥-314.92 Million | CN¥149.68 Million | ▼ -78.8% |
| 2021 | -1.18x | CN¥-227.82 Million | CN¥193.59 Million | ▲ +2.3% |
| 2020 | -1.20x | CN¥-243.66 Million | CN¥202.33 Million | ▼ -19.0% |
| 2019 | -1.01x | CN¥-81.43 Million | CN¥80.50 Million | — |